NASDAQ · Biotechnology

HALO (HALO) Stock

$81.48 -0.55% NASDAQ: HALO Healthcare

Valuation

MetricValue
Price$81.48
Market Cap$9.66B
P/E Ratio23.58
P/B Ratio36.26
P/S Ratio5.28
EPS (TTM)$2.56
52-Week High$82.22
52-Week Low$51.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE99.40%
ROA22.06%
ROCE1700.00%
Gross Margin76.93%
Operating Margin56.96%
Net Margin23.13%
Debt/Equity9.76
Current Ratio4.66

Annual Financials (USD)

Metric20212022202320242025
Revenue$443.0M$660.0M$829.0M$1.0B$1.4B
Operating Profit$276.0M$268.0M$338.0M$551.0M$816.0M
Net Profit$403.0M$202.0M$282.0M$444.0M$317.0M
EPS$2.74$1.44$2.10$3.43$2.56
Op Margin62.2%40.5%40.7%54.3%58.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.8B$1.7B$2.1B$2.5B
Total Liabilities$907.0M$1.7B$1.6B$1.7B$2.5B
Cash$119.0M$234.0M$118.0M$116.0M$134.0M
Borrowings$877.0M$1.5B$1.5B$1.5B$2.1B

Latest News

Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment Insider Monkey · Jul 15, 2026 1 Value Stock Worth Investigating and 2 Facing Headwinds StockStory · Jul 15, 2026 HALO: Lowering target price to $83.00 Argus Research · Jul 15, 2026 2 Reasons to Like HALO and 1 to Stay Skeptical StockStory · Jul 10, 2026 1 Surging Stock for Long-Term Investors and 2 We Brush Off StockStory · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$299.0M$240.0M$389.0M$479.0M$652.0M
Investing Cash Flow$-408.0M$-492.0M$-112.0M$-273.0M$-553.0M
Financing Cash Flow$-338.0M$-262.0M$-395.0M$-219.0M$-558.0M
Net Cash Flow$-29.0M$115.0M$-116.0M$-3.0M$21.0M
Free Cash Flow$298.0M$235.0M$373.0M$468.0M$645.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.45
EV / EBITDA10.62
FCF Yield8.38%
Quick Ratio2.33
Interest Coverage45.33
Return 1Y40.56%
Return 3Y83.26%
Return 5Y85.07%

Ownership

Insiders Held1.07%
Institutions Held108.51%
Institutions Float Held109.68%
Institutional HolderSharesReport Date
Blackrock Inc.13,265,0532026-03-31
Vanguard Capital Management LLC5,271,2182026-03-31
Vanguard Portfolio Management LLC5,249,2062026-03-31
State Street Corporation4,937,8542026-03-31
Invesco Ltd.4,012,4942026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABVXAbivax S.A. $136.94 +1.50% -24.37 $10.06B 0.00%
ATR $136.77 +2.10% 19.32 $8.73B 1.66%
CAI $16.45 +2.17% 49.96 $4.65B 0.00%
CORT $91.12 -4.45% 146.17 $9.78B 0.00%
CYTKCytokinetics, Incorporated $80.62 -0.15% -11.82 $10.03B 0.00%

About HALO

HALO is led by CEO Helen I. Torley, employs 423 people, headquartered in San Diego, US, publicly traded since 2004.

HALO stock trades at $81.48 with a market capitalization of $9.66B. The stock is valued at a price-to-earnings (P/E) ratio of 23.58, price-to-book of 36.26, price-to-sales of 5.28. Over the past 52 weeks the stock has ranged between $51.06 and $82.22, and currently trades at its 52-week high.

On profitability, HALO generates a return on equity (ROE) of 99.40% — well above the market average, a sign of a high-quality business, return on capital employed of 1700.00%, an operating margin of 56.96%, a net profit margin of 23.13%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides